April 12th, 2008
G&H’s INTERVIEW WITH NAVIGENICS
Navigenics approached Genetics and Health for an interview. With so much written about similar genomics companies such as 23andme, Knome, deCODE genetics, I was intrigued to learn more about this company. In particular, Navigenics appears to be the only company within this industry genre who provides a comprehensive wellness model – a […]
By Elaine -- 3 comments
April 11th, 2008
Concluding G&H’s exclusive interview with Navigenics’ Medical Director Dr Michael Nierenberg, we explore the challenges faced by Navigenics to integrate its genomic services into mainstream medicine …
When founding my old company Opaldia, probably the single most challenging aspect of early adoption of genetic testing was physician barriers. Mostly this was borne out of a genuine lack of understanding […]
By Elaine -- 0 comments
April 11th, 2008
Continuing G&H’s exclusive interview with Navigenics’ Medical Director Dr Michael Nierenberg, we explore the whole issue of privacy, insurance, GINA and ethics…..
One of the main consumer concerns is that of privacy of information, both in terms that a genetic test has been undertaken but also that the results of the test are kept private and out of the […]
By Elaine -- 1 comment
April 10th, 2008
In this fifth article in the series of articles originating from G&H’s exclusive interview with Navigenics’ Medical Director, Dr Michael Nierenberg, we explore the contentious issue of whole genomic testing.
Navigenics uses Affymetrix’s gene chip which is able to test around 1 million genetic markers. However Navigenics has initially focused on 18 specific, treatable diseases which […]
By Elaine -- 1 comment
April 9th, 2008
In this fourth in the series of articles originating from G&H’s exlusive interview with Navigenics’ Medical Director Dr Michael Nierenberg, we look at the whole issue of low penetrance versus high penetrance gene testing.
SNPs are known as ‘low penetrance genes’ where it will only sometimes produce the symptom or trait with which it has been associated […]
By Elaine -- 1 comment
April 9th, 2008
In this third article originating from G&H’s exclusive interview with Navigenics’ Medical Director, Dr Michael Nierenberg, we explore the whole issue of SNP testing and how SNPs can be used in disease risk assessment.
Navigenics has focused on around 100 of the most definitive research papers on SNPs (single nucleotide polymorphisms) that have been most strongly associated […]
By Elaine -- 2 comments
April 7th, 2008
Navigenics approached Genetics and Health for an interview. With so much written about similar genomics companies such as 23andme, Knome, deCODE genetics, I was intrigued to learn more about this company. In particular, Navigenics appears to be the only company within this industry genre who provides a comprehensive wellness model – a healthcare model that […]
By Elaine -- 1 comment
March 26th, 2008
As readers of Genetics and Health know, I am vocal in my support of providing patients with a wealth of education, information and advice before, during and after they undergo a genetic test.
With this in mind, Navigenics is a company I have had my eye on for some-while. The company offers a comprehensive SNP based genetic risk assessment screen but has […]
By Elaine -- 0 comments
Recent Comments